当代肺动脉高压的诊断、治疗与临床管理综述
该综述指出肺动脉高压(PAH)的临床特征已较最初描述发生显著变化:诊断时年龄更大、男性病情更重、结缔组织病相关PAH为高危亚组。风险分层量表可用于床旁指导治疗目标,初始联合治疗对未治疗患者至关重要,接受联合治疗者3年生存率可达84%。但转诊医生评估不完整和误诊仍常见,导致不当治疗。
要点
- PAH患者诊断时年龄较前增大,男性病情更重,结缔组织病相关PAH为高危亚组。
- 风险分层量表可用于床旁指导治疗目标,包括6分钟步行距离>440 m等指标。
- 初始联合治疗对未治疗患者至关重要,联合治疗者3年生存率可达84%。
核心结论
- PAH已演变为可治疗的当代疾病,生存改善且治疗成功标准提高,但早期准确诊断的意识不足仍是可逆的不良结局原因。
研究设计与样本
- 综述,纳入PAH诊断、治疗与临床管理相关文献,未报告系统检索范围与样本量。
主要发现
- PAH临床特征已变化:诊断时年龄较前更大,男性病情较女性更重,结缔组织病相关PAH为高危亚组。
- 接受联合治疗的患者3年生存率可高达84%,而1980-1985年NIH特发性PAH注册研究为48%。
- 转诊医生临床评估不完整和误诊常见,并与不当治疗相关。
关键数值与推荐
- 治疗目标包括6分钟步行距离>440 m、峰值氧耗量>15 mL/min/kg、右心房面积<18 cm2、心脏指数>2.5 L/min/m2、日常活动症状负荷缺如或低。
- 目前临床使用14种靶向6个PAH特异性分子中介的疗法。
- 初始联合治疗对未治疗患者至关重要。
临床怎么用
- 床旁使用风险分层量表指导治疗目标。
- 对未治疗患者考虑初始联合治疗。
- 提高对早期准确诊断PAH的重视,避免评估不完整和误诊导致不当治疗。
局限性
- 为综述,未报告系统检索策略、纳入标准及样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pulmonary arterial hypertension (PAH) is characterized by severe remodeling of the distal pulmonary arteries, increased pulmonary vascular resistance, and right ventricular dysfunction that promotes heart failure. Once regarded as largely untreatable, evidence-based decision making now guides clinical management of PAH and improves outcomes. However, misconceptions regarding the approach to PAH in the modern era are common and associated with substandard clinical care. OBSERVATIONS: The clinical profile of PAH has changed substantially since its original description. Patients are older at diagnosis than previously reported; disease severity appears greater in men compared with women; and patients with PAH in association with connective tissue disease are identified as a particularly high-risk subgroup. Risk stratification scales for PAH are now available at point of care, which inform treatment goals, including a 6-minute walk distance of greater than 440 m, peak volume of oxygen consumption of greater than 15 mL/min/kg, right atrial area of less than 18 cm2, cardiac index of greater than 2.5 L/min/m2, and absent or low symptom burden with routine physical activity. At present, 14 therapies targeting 6 PAH-specific molecular intermediaries are used clinically. Recent landmark trial data have demonstrated the critical importance of initial combination therapy in treatment-naive patients. These findings underscore a global shift in PAH that couples early disease detection with aggressive pharmacotherapy. Indeed, recent longitudinal data from patients receiving combination therapy show that the 3-year survival rate in PAH may be as high as 84% compared with 48% from the original National Institutes of Health registry on idiopathic PAH (1980-1985). Despite these gains, incomplete clinical evaluation and misdiagnosis by referring clinicians is common and associated with inappropriate therapy. CONCLUSIONS AND RELEVANCE: Compared with the original clinical experience, PAH has evolved into a contemporary and treatable disease characterized by improved survival and a high standard for defining therapeutic success. However, underawareness among clinicians regarding the importance of early and accurate PAH diagnosis persists and is a potentially reversible cause of adverse outcome in this disease.
引用
- Maron BA, Galiè N. Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review. JAMA Cardiol. 2016. PMID: 27851839. doi:10.1001/jamacardio.2016.4471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。